Novo Nordisk Pays $6.3M To Settle False Claims Over ‘Non-Designated’ Needles
NEWARK, N.J. — Novo Nordisk Inc. on Aug. 30 agreed to pay $6.3 million to settle allegations that it violated the False Claims Act by selling needles that were manufacturer in...To view the full article, register now.
Already a subscriber? Click here to view full article